{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Stable disease, partial response, complete response or disease progression.","groups":[{"description":"ABC294640 250 mg BID given continuously","id":"OG000","title":"ABC294640 250 mg BID"},{"description":"ABC294640 250 mg BID given continuously","id":"OG001","title":"ABC294640 500 mg BID"},{"description":"ABC294640 750 mg BID given continuously","id":"OG002","title":"ABC294640 750 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent to treat","reportingStatus":"POSTED","timeFrame":"After 3 cycles (12 weeks) of treatment","title":"To Assess the Antitumor Activity of Single Agent Opaganib in Patients With Refractory or Relapsed Multiple Myeloma After 3 Cycles of Treatment.","type":"SECONDARY","unitOfMeasure":"Participants"}